
Sign up to save your podcasts
Or


Episode Summary
Ryan Long — former senior policy advisor to Speaker Kevin McCarthy and current non-resident senior scholar at the USC Schaefer Institute — joins Drs. Koka and DiGiorgio for a deep dive into the structural failures driving American drug pricing. The conversation covers the list-to-net price bubble and why patients pay cost-sharing on a fictitious number, how the IRA's price-setting mechanism disincentivizes both new drug development and subsequent indications, and why the 340B program — sold politically as a lifeline for safety net hospitals — systematically funnels the most money to wealthy health systems with high commercial payer mixes. Long argues the fix isn't tweaking the formula; it's scrapping the drug arbitrage mechanism entirely and replacing it with a direct, transparent grant program that actually reaches the hospitals that need it.
Chapter Markers
00:00 Introduction — Ryan Long's 25 Years in Health Policy
02:08 Drug Pricing 101: List Price vs. Net Price and Why It Matters
06:39 GLP-1s as a Case Study: Insurance Pullback and the Price War That Followed
11:17 The Medicare Bridge Program and Government Price Setting for GLP-1s
14:11 Why Drug Companies Set List Prices High at Launch
16:10 The Inflation Reduction Act: Price Controls, Rebate Penalties, and Innovation Risk
20:57 Brand-to-Brand Competition and the FDA's Role
28:52 GLP-1s Under Medicare: Is the $50/Month Bridge Program Good Policy?
36:50 The Medicaid Drug Rebate Program and the Best Price Provision
38:08 The Origins of 340B: What the Program Was Actually Designed to Do
42:24 Qui Bono — How 340B Revenue Is Really Generated
50:17 Contract Pharmacies and the For-Profit Middlemen in 340B
56:31 The Humira Biosimilar Case and the Rebate Trap
1:02:58 The 1987 Supreme Court Case That Supercharged the Rebate Structure
1:05:26 Broad Reform Proposals: From 340B Overhaul to Consolidation
1:09:19 Closing Thoughts and Where to Find Ryan's Work
Co-Host Handles
@anish_koka and @drdigiorgio
Show Handle
@drsloungepod
Subscribe Links
Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR
Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658
YouTube: https://www.youtube.com/@TheDoctorsLoungePod
By The Doctor's Lounge4.9
4343 ratings
Episode Summary
Ryan Long — former senior policy advisor to Speaker Kevin McCarthy and current non-resident senior scholar at the USC Schaefer Institute — joins Drs. Koka and DiGiorgio for a deep dive into the structural failures driving American drug pricing. The conversation covers the list-to-net price bubble and why patients pay cost-sharing on a fictitious number, how the IRA's price-setting mechanism disincentivizes both new drug development and subsequent indications, and why the 340B program — sold politically as a lifeline for safety net hospitals — systematically funnels the most money to wealthy health systems with high commercial payer mixes. Long argues the fix isn't tweaking the formula; it's scrapping the drug arbitrage mechanism entirely and replacing it with a direct, transparent grant program that actually reaches the hospitals that need it.
Chapter Markers
00:00 Introduction — Ryan Long's 25 Years in Health Policy
02:08 Drug Pricing 101: List Price vs. Net Price and Why It Matters
06:39 GLP-1s as a Case Study: Insurance Pullback and the Price War That Followed
11:17 The Medicare Bridge Program and Government Price Setting for GLP-1s
14:11 Why Drug Companies Set List Prices High at Launch
16:10 The Inflation Reduction Act: Price Controls, Rebate Penalties, and Innovation Risk
20:57 Brand-to-Brand Competition and the FDA's Role
28:52 GLP-1s Under Medicare: Is the $50/Month Bridge Program Good Policy?
36:50 The Medicaid Drug Rebate Program and the Best Price Provision
38:08 The Origins of 340B: What the Program Was Actually Designed to Do
42:24 Qui Bono — How 340B Revenue Is Really Generated
50:17 Contract Pharmacies and the For-Profit Middlemen in 340B
56:31 The Humira Biosimilar Case and the Rebate Trap
1:02:58 The 1987 Supreme Court Case That Supercharged the Rebate Structure
1:05:26 Broad Reform Proposals: From 340B Overhaul to Consolidation
1:09:19 Closing Thoughts and Where to Find Ryan's Work
Co-Host Handles
@anish_koka and @drdigiorgio
Show Handle
@drsloungepod
Subscribe Links
Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR
Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658
YouTube: https://www.youtube.com/@TheDoctorsLoungePod

8,340 Listeners

153,248 Listeners

4,892 Listeners

2,446 Listeners

3,360 Listeners

278 Listeners

10,182 Listeners

39,483 Listeners

2,477 Listeners

8,439 Listeners

3,386 Listeners

419 Listeners

16,332 Listeners

43 Listeners

153 Listeners